The role of angiogenesis in malignant pleural effusion: from basic research to clinical application

Area of Science:

• Oncology
• Pulmonology
• Molecular Biology

Background:

• Malignant pleural effusion (MPE) signifies advanced cancer, particularly lung cancer, and indicates a poor prognosis.
• Current MPE management is primarily palliative, highlighting the need for novel therapeutic strategies.
• Understanding MPE pathogenesis is crucial for developing more effective treatments.

Purpose of the Study:

• To review recent advancements in the mechanisms underlying MPE formation.
• To provide an overview of current targeted therapies, focusing on the vascular endothelial growth factor (VEGF) pathway.
• To retrospectively analyze the efficacy of bevacizumab in treating MPE in lung adenocarcinoma patients.

Main Methods:

• Literature review on MPE pathogenesis and VEGF pathway inhibitors.
• Retrospective analysis of 19 lung adenocarcinoma patients with MPE treated at West China Hospital.
• Evaluation of bevacizumab efficacy via different administration routes for MPE.

Main Results:

• Recent research has elucidated key mechanisms in MPE development.
• VEGF pathway inhibitors, like bevacizumab, represent a promising targeted therapy approach.
• Bevacizumab demonstrated potential efficacy in managing MPE in the studied lung adenocarcinoma cohort.

Conclusions:

• Advances in understanding MPE pathogenesis pave the way for targeted therapeutic interventions.
• Bevacizumab shows promise as a therapeutic option for malignant pleural effusion in lung adenocarcinoma.
• Further research is warranted to optimize bevacizumab administration for MPE treatment.